» Articles » PMID: 35304983

Modifying the Diet and Gut Microbiota to Prevent and Manage Neurodegenerative Diseases

Overview
Journal Rev Neurosci
Publisher De Gruyter
Specialty Neurology
Date 2022 Mar 19
PMID 35304983
Authors
Affiliations
Soon will be listed here.
Abstract

The global prevalence of Alzheimer's disease and Parkinson's disease is steadily increasing due to the aging population. The lack of effective drugs against these neurodegenerative disorders makes it imperative to identify new strategies for their prevention and treatment. Recent studies have revealed that harnessing the power of the gut microbiota through modification of diet may be a valuable approach for reducing the risk, modulating the symptoms, and ameliorating the pathophysiological aspects of neurodegenerative diseases. Consuming specific dietary components can alter the prevalence of bacterial communities within the gut to a healthy enterotype, which can influence the production of beneficial metabolites by microbiota. This article focuses on several dietary components, which have been demonstrated to affect the gut microbiota-brain axis and therefore could lead to attenuation of specific pathological processes in neurodegenerative diseases. Published evidence indicates that fermented foods, including kefir, and foods that are high in bioactive polyphenols and complex carbohydrates, such as grapes, pomegranates, and seaweed, may be effective at reducing neuroinflammation, oxidative stress, neurotransmitter dysfunction, and neuronal death associated with Alzheimer's and Parkinson's diseases. Even though experimental evidence supporting the protective properties of the above dietary components in these diseases is emerging, it is evident that further human clinical studies are required to conclusively establish the benefits of any suggested dietary interventions. The translational potential of such research is illustrated by the clinical success of the recently developed Alzheimer's drug, GV-971, which is a seaweed derivative that works by modulating the gut microbiota-brain axis.

Citing Articles

The role of the gut microbiota in neurodegenerative diseases targeting metabolism.

Fu Y, Gu Z, Cao H, Zuo C, Huang Y, Song Y Front Neurosci. 2024; 18:1432659.

PMID: 39391755 PMC: 11464490. DOI: 10.3389/fnins.2024.1432659.


Involvement of Aryl Hydrocarbon Receptor in Longevity and Healthspan: Insights from Humans, Mice, and .

Serna E, Verdu D, Valls A, Belenguer-Varea A, Tarazona-Santabalbina F, Borras C Int J Mol Sci. 2024; 25(18).

PMID: 39337431 PMC: 11432571. DOI: 10.3390/ijms25189943.


Pomegranate ( L.) Extract Effects on Inflammaging.

Cordiano R, Gammeri L, Di Salvo E, Gangemi S, Minciullo P Molecules. 2024; 29(17).

PMID: 39275022 PMC: 11396831. DOI: 10.3390/molecules29174174.


The effects of nitric oxide in Alzheimer's disease.

Wang L, Lu D, Wang X, Wang Z, Li W, Chen G Med Gas Res. 2024; 14(4):186-191.

PMID: 39073326 PMC: 11257180. DOI: 10.4103/2045-9912.385939.


The Postbiotic Properties of Butyrate in the Modulation of the Gut Microbiota: The Potential of Its Combination with Polyphenols and Dietary Fibers.

Maiuolo J, Bulotta R, Ruga S, Nucera S, Macri R, Scarano F Int J Mol Sci. 2024; 25(13).

PMID: 39000076 PMC: 11240906. DOI: 10.3390/ijms25136971.


References
1.
Seppala T, Herukka S, Hanninen T, Tervo S, Hallikainen M, Soininen H . Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry. 2010; 81(10):1123-7. PMC: 2976614. DOI: 10.1136/jnnp.2010.205757. View

2.
Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T . Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019; 29(10):787-803. PMC: 6796854. DOI: 10.1038/s41422-019-0216-x. View

3.
Chen Z, Zhong C . Oxidative stress in Alzheimer's disease. Neurosci Bull. 2014; 30(2):271-81. PMC: 5562667. DOI: 10.1007/s12264-013-1423-y. View

4.
He Q, Liu J, Liang J, Liu X, Li W, Liu Z . Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective. Cells. 2018; 7(4). PMC: 5946101. DOI: 10.3390/cells7040024. View

5.
Batista L, Malta S, Silva H, Borges L, Rocha L, da Silva J . Kefir metabolites in a fly model for Alzheimer's disease. Sci Rep. 2021; 11(1):11262. PMC: 8160324. DOI: 10.1038/s41598-021-90749-8. View